MLYS Stock Cash Flow Statements

Mineralys Therapeutics . Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Mineralys Therapeutics . Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31

cash flows from operating activities:
net income	-43,274,000	-42,211,000	-48,946,000	-56,342,000	-41,014,000	-31,508,000	-24,389,000	-22,760,000	-12,141,000	-12,608,000
adjustments to reconcile net income to net cash from operating activities:
accretion of discount on held-to-maturity securities	-2,229,000	-1,046,000	-1,337,000	-2,712,000	-2,847,000	-2,509,000	-2,066,000	-1,962,000	-1,982,000	-855,000
stock-based compensation	4,553,000	3,645,000	3,134,000	3,139,000	2,872,000	2,191,000	1,457,000	1,578,000	1,276,000	749,000
depreciation and amortization	16,000	15,000	15,000	11,000	9,000	8,000
changes in operating assets and liabilities:
accrued interest receivable	-47,000	52,000	98,000	23,000	184,000	119,000	300,000	-219,000	-166,000	-270,000
prepaid, other current assets, and other assets	1,738,000	-4,396,000
accounts payable and accrued liabilities	9,074,000	-1,546,000	-16,674,000	2,964,000	9,472,000	8,401,000	-3,061,000	7,336,000	-3,772,000	1,912,000
net cash from operating activities	-30,169,000	-45,487,000	-66,843,000	-50,186,000	-30,146,000	-19,139,000	-28,981,000	-19,031,000	-20,386,000	-12,775,000
capex	0	0	0	-37,000	0	-59,000	0	0	0	0
free cash flows	-30,169,000	-45,487,000	-66,843,000	-50,223,000	-30,146,000	-19,198,000	-28,981,000	-19,031,000	-20,386,000	-12,775,000
cash flows from investing activities:
purchases of marketable securities	-117,881,000	-127,876,000
maturities of marketable securities	75,000,000	35,000,000
purchases of property and equipment			0	-37,000	0	-59,000
net cash from investing activities	-42,881,000	-92,876,000	83,570,000	79,605,000	7,736,000	-55,952,000	-8,089,000	4,007,000	-16,139,000	-140,251,000
cash flows from financing activities:
proceeds from issuance of common stock in public offering, net of offering costs	-286,000	189,166,000
proceeds from issuance of common stock pursuant to atm agreement, net of issuance costs
proceeds from stock option exercises	1,079,000	123,000	54,000	40,000	54,000	149,000	10,000
proceeds from issuance of common stock for cash under employee stock purchase plan
payment of shelf offering costs	-47,000	-10,000
proceeds from issuance of common stock and pre-funded warrants in a private placement offering, net of offering costs
net cash from financing activities	9,831,000	189,279,000	90,000	-1,000	-152,000	116,205,000	74,000	184,000	-581,000	203,571,000
net increase in cash and cash equivalents	-63,219,000	50,916,000	16,817,000	29,418,000	-22,562,000	41,114,000	-36,996,000	-14,840,000
cash and cash equivalents - beginning	0	114,091,000	0
cash and cash equivalents - ending	-63,219,000	165,007,000	16,817,000	29,418,000	-22,562,000	90,418,000	-36,996,000	-14,840,000
supplement disclosure of non-cash financing activities:
funds receivable from the sale of common stock pursuant to atm agreement, net of issuance costs
offering costs included in accounts payable and accrued liabilities					-279,000	321,000
public offering and shelf offering costs included in accounts payable and accrued liabilities		289,000
prepaid and other current assets			-3,133,000	2,731,000	1,178,000	4,159,000	-1,222,000	-3,004,000	-3,601,000	-1,703,000
purchase of marketable securities			-63,930,000	-58,858,000	-127,264,000	-123,393,000	-73,089,000	-55,993,000	-56,139,000	-162,751,000
maturity of marketable securities			147,500,000	138,500,000	135,000,000	67,500,000	65,000,000	60,000,000	40,000,000	22,500,000
proceeds from issuance of common stock and pre-funded warrants in a private placement offering, net of paid offering costs			0	0	-60,000	116,119,000
proceeds from the issuance of common stock for cash under employee stock purchase plan			83,000	0
offering costs paid			-47,000	-41,000	-284,000	-63,000
proceeds from issuance of common stock in initial public offering, net of offering costs
conversion of convertible preferred stock to common stock upon closing of initial public offering							0	0	0	159,180,000
cash, cash equivalents, and restricted cash - beginning					0	49,304,000	0	0	0	87,701,000
issuance of common stock in initial public offering, net of offering costs							0	0	-581,000	203,571,000
proceeds from the issuance of series a convertible preferred stock, net of offering costs
proceeds from the issuance of series b convertible preferred stock, net of offering costs
deferred offering costs included in accounts payable and accrued liabilities										581,000
net increase in cash, cash equivalents, and restricted cash										50,545,000
cash, cash equivalents, and restricted cash - ending										138,246,000
change in fair value of convertible notes
non-cash interest expense
deferred offering costs
conversion of convertible notes and accrued interest to series a convertible preferred stock

We provide you with 20 years of cash flow statements for Mineralys Therapeutics . stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Mineralys Therapeutics . stock. Explore the full financial landscape of Mineralys Therapeutics . stock with our expertly curated income statements.

The information provided in this report about Mineralys Therapeutics . stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.